Literature DB >> 29265576

Sensitivity and specificity of the lymphocyte transformation test in drug reaction with eosinophilia and systemic symptoms causality assessment.

R Cabañas1,2, O Calderón1, E Ramírez2,3, A Fiandor1,2, T Caballero1, R Heredia1, P Herranz2,4, R Madero5, S Quirce1, T Bellón2,6.   

Abstract

BACKGROUND: Drug reaction with eosinophilia and systemic symptoms (DRESS) is a severe delayed hypersensitivity reaction. The determination of drug causality is complex. The lymphocyte transformation test (LTT) has been reported positive in more than 50% of DRESS cases. Nevertheless, the sensitivity and specificity of LTT specifically in DRESS have not yet been established. Rechallenge with the culprit drug is contraindicated and cannot be used as gold standard for sensitivity and specificity determination.
OBJECTIVE: To estimate the sensitivity and specificity of LTT in a clinically defined series of patients with DRESS.
METHODS: Some 41 patients diagnosed with DRESS were included in the study. The results of the algorithm of the Spanish Pharmacovigilance System were used as the standard for a correct diagnosis of drug causality. A standard LTT was performed with involved drugs in acute or recovery samples. A stimulation index (SI) ≥2 in at least one concentration except for beta-lactams (SI ≥3) and contrast media (SI ≥4) was considered positive. Contingency tables and ROC curves were used for analysis.
RESULTS: Sensitivity and specificity of LTT in the recovery phase of DRESS were 73% and 82%, respectively, whereas in the acute phase, they were only 40% and 30%, respectively. Comparison of skin tests and LTT confirmed a higher sensitivity and specificity of LTT in DRESS. LTT showed high sensitivity (S) and specificity (Sp) for anticonvulsants (S 100%, Sp 100%; P = .008), anti-TB drugs (S 87.5%, Sp 100%; P = .004), and beta-lactams (S 73%, Sp 100%; P = .001). ROC curves revealed that the best criteria for LTT positivity for all drugs are SI ≥2 in at least one concentration, increasing overall sensitivity to 80%, and for beta-lactams from 73% to 92%. CONCLUSIONS AND CLINICAL RELEVANCE: LTT is a good diagnostic tool for drug causality in DRESS, mainly when performed in the recovery phase.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  T cells; drug allergy; immunologic tests

Mesh:

Year:  2018        PMID: 29265576     DOI: 10.1111/cea.13076

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  9 in total

1.  Application of High-Efficiency Cell Expansion and High-Throughput Drug Sensitivity Screening for Leukemia Treatment.

Authors:  Lili Li; Wenliang Wang; Li Liang; Jian Ge; Ruixiang Xia
Journal:  Dis Markers       Date:  2022-07-05       Impact factor: 3.464

Review 2.  Drug Reaction with Eosinophilia and Systemic Symptoms (DReSS)/Drug-Induced Hypersensitivity Syndrome (DiHS)-Readdressing the DReSS.

Authors:  Hannah Stirton; Neil H Shear; Roni P Dodiuk-Gad
Journal:  Biomedicines       Date:  2022-04-26

3.  Drug-Induced Hypersensitivity Syndrome (DIHS)/Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS): Clinical Features and Pathogenesis.

Authors:  Natsumi Hama; Riichiro Abe; Andrew Gibson; Elizabeth J Phillips
Journal:  J Allergy Clin Immunol Pract       Date:  2022-02-15

Review 4.  Clinical value of in vitro tests for the management of severe drug hypersensitivity reactions.

Authors:  Yuttana Srinoulprasert; Ticha Rerkpattanapipat; Mongkhon Sompornrattanaphan; Chamard Wongsa; Duangjit Kanistanon
Journal:  Asia Pac Allergy       Date:  2020-10-29

Review 5.  Updates and Insights in the Diagnosis and Management of DRESS Syndrome.

Authors:  Elisa Maria Schunkert; Sherrie Jill Divito
Journal:  Curr Dermatol Rep       Date:  2021-11-09

6.  The Role of In Vitro Detection of Drug-Specific Mediator-Releasing Cells to Diagnose Different Phenotypes of Severe Cutaneous Adverse Reactions.

Authors:  Jettanong Klaewsongkram; Supranee Buranapraditkun; Pattarawat Thantiworasit; Pawinee Rerknimitr; Papapit Tuchinda; Leena Chularojanamontri; Ticha Rerkpattanapipat; Kumutnart Chanprapaph; Wareeporn Disphanurat; Panlop Chakkavittumrong; Napatra Tovanabutra; Chutika Srisuttiyakorn; Yuttana Srinoulprasert; Chonlaphat Sukasem; Yuda Chongpison
Journal:  Allergy Asthma Immunol Res       Date:  2021-11       Impact factor: 5.764

Review 7.  Antibiotic Allergy De-Labeling: A Pathway against Antibiotic Resistance.

Authors:  Inmaculada Doña; Marina Labella; Gádor Bogas; Rocío Sáenz de Santa María; María Salas; Adriana Ariza; María José Torres
Journal:  Antibiotics (Basel)       Date:  2022-08-03

8.  Development and initial validation of a modified lymphocyte transformation test (LTT) assay in patients with DRESS and AGEP.

Authors:  Chris Weir; Jamma Li; Richard Fulton; Suran L Fernando
Journal:  Allergy Asthma Clin Immunol       Date:  2022-10-09       Impact factor: 3.373

9.  Cutaneous and systemic hyperinflammation drives maculopapular drug exanthema in severely ill COVID-19 patients.

Authors:  Yasutaka Mitamura; Daniel Schulz; Saskia Oro; Nick Li; Isabel Kolm; Claudia Lang; Reihane Ziadlou; Ge Tan; Bernd Bodenmiller; Peter Steiger; Angelo Marzano; Nicolas de Prost; Olivier Caudin; Mitchell Levesque; Corinne Stoffel; Peter Schmid-Grendelmeier; Emanual Maverakis; Cezmi A Akdis; Marie-Charlotte Brüggen
Journal:  Allergy       Date:  2021-07-19       Impact factor: 14.710

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.